
GLP-1 Weight-Loss Drugs: Quick Gains, Uncertain Long-Term Risks
GLP-1 drugs such as Wegovy, Ozempic, and Mounjaro—originally diabetes medications—have surged as weight‑loss aids, delivering notable losses for many who pair the injections with diet and exercise. Doctors warn long‑term effects are not well understood, with potential side effects from nausea to pancreatitis and gallbladder issues, and a risk of muscle loss if people aren’t active or get enough protein. Evidence also suggests weight often returns after stopping the medication, though fat rebound vs. muscle loss varies. Access and cost vary widely, with insurance helping some patients but non‑FDA‑approved compounded versions raising safety concerns.













